180 related articles for article (PubMed ID: 25900749)
1. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures.
Selby R; Geerts WH; Kreder HJ; Crowther MA; Kaus L; Sealey F;
J Orthop Trauma; 2015 May; 29(5):224-30. PubMed ID: 25900749
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
3. Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial.
Goel DP; Buckley R; deVries G; Abelseth G; Ni A; Gray R
J Bone Joint Surg Br; 2009 Mar; 91(3):388-94. PubMed ID: 19258618
[TBL] [Abstract][Full Text] [Related]
4. Chemoprophylaxis for Venous Thromboembolism in Operative Treatment of Fractures of the Tibia and Distal Bones: A Systematic Review and Meta-analysis.
Patterson JT; Morshed S
J Orthop Trauma; 2017 Sep; 31(9):453-460. PubMed ID: 28459774
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic venous thromboembolism uncommon without thromboprophylaxis after isolated lower-limb fracture: the knee-to-ankle fracture (KAF) cohort study.
Selby R; Geerts WH; Kreder HJ; Crowther MA; Kaus L; Sealey F
J Bone Joint Surg Am; 2014 May; 96(10):e83. PubMed ID: 24875035
[TBL] [Abstract][Full Text] [Related]
6. Low-Molecular-Weight Heparin Did Not Differ from Placebo in Preventing Clinically Important Deep Venous Thrombosis After Surgical Repair of Leg Fracture.
Little MT
J Bone Joint Surg Am; 2016 Feb; 98(4):316. PubMed ID: 26888681
[No Abstract] [Full Text] [Related]
7. Effect of Chemical Thromboprophylaxis on the Rate of Venous Thromboembolism After Treatment of Foot and Ankle Fractures.
Zheng X; Li DY; Wangyang Y; Zhang XC; Guo KJ; Zhao FC; Pang Y; Chen YX
Foot Ankle Int; 2016 Nov; 37(11):1218-1224. PubMed ID: 27521353
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
[TBL] [Abstract][Full Text] [Related]
9. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
10. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a clinical trial of a low-molecular-weight heparin in preventing clinically important venous thromboembolism in medical patients: the prospective evaluation of dalteparin efficacy for prevention of venous thromboembolism in immobilized patients trial (the PREVENT study).
Vaitkus PT; Leizorovicz A; Goldhaber SZ;
Vasc Med; 2002; 7(4):269-73. PubMed ID: 12710842
[TBL] [Abstract][Full Text] [Related]
12. Is routine chemoprophylaxis necessary for prevention of venous thromboembolism following knee arthroplasty in a low incidence population?
Cho KY; Kim KI; Khurana S; Bae DK; Jin W
Arch Orthop Trauma Surg; 2013 Apr; 133(4):551-9. PubMed ID: 23381297
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
14. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
Andreozzi GM; Bignamini AA; Davì G; Palareti G; Matuška J; Holý M; Pawlaczyk-Gabriel K; Džupina A; Sokurenko GY; Didenko YP; Andrei LD; Lessiani G; Visonà A;
Circulation; 2015 Nov; 132(20):1891-7. PubMed ID: 26408273
[TBL] [Abstract][Full Text] [Related]
15. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Fuji T; Ochi T; Niwa S; Fujita S
J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
[TBL] [Abstract][Full Text] [Related]
16. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
[TBL] [Abstract][Full Text] [Related]
17. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial.
Karthaus M; Kretzschmar A; Kröning H; Biakhov M; Irwin D; Marschner N; Slabber C; Fountzilas G; Garin A; Abecasis NG; Baronius W; Steger GG; Südhoff T; Giorgetti C; Reichardt P
Ann Oncol; 2006 Feb; 17(2):289-96. PubMed ID: 16317012
[TBL] [Abstract][Full Text] [Related]
18. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial.
Khorana AA; Francis CW; Kuderer NM; Carrier M; Ortel TL; Wun T; Rubens D; Hobbs S; Iyer R; Peterson D; Baran A; Kaproth-Joslin K; Lyman GH
Thromb Res; 2017 Mar; 151():89-95. PubMed ID: 28139259
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
20. Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
Cohen AT; Turpie AG; Leizorovicz A; Olsson CG; Vaitkus PT; Goldhaber SZ;
Vasc Med; 2007 May; 12(2):123-7. PubMed ID: 17615800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
